Take a look at our previous reports:

Our first approved medicine

In 2021, we made significant progress with our Jyseleca (filgotinib) franchise. In September, we celebrated Jyseleca’s first year on the market following the approval for the treatment of adult patients with moderate to severe active RA in the European Union, Great Britain, and Japan. Following the amended agreement with Gilead from late 2020, we successfully completed the transfer of commercial activities from Gilead, and we are the proud MAH of Jyseleca in the European Economic Area (EEA) and Great Britain since December 2021. In addition, filgotinib is now also approved in the European Union and Great Britain for the treatment of adult patients with moderate to severe UC, adding a second indication for filgotinib.

After years of hard work by so many, we are very excited to bring a new treatment option to patients living with RA and UC throughout Europe.

The market for anti-inflammatory drugs in Europe is considerable: it is estimated that the inflammation market today in the five largest European markets is worth approximately €6.1 billion, with about 50% of the current market going to RA therapies and about 50% to UC and CD combined:

EU5 inflammation market in 2021, €B

EU5 inflammation market today, €B  (pie chart)
RA: rheumatoid arthritis CD: Crohn’s disease UC: ulcerative colitis
Source: RA (DRG 2021), IBD (source range estimation from DRG, Pharma Intelligence, IQVIA 2021). All biologics and tsDMARDs.1

It is our ambition that by the second half of this decade, Jyseleca could generate peak sales of ~€500 million in RA, UC, and CD in Europe, targeting an 8 – 12% share of the total estimated market for RA, UC, and CD in the five largest markets in Europe.

Formerly known as GLPG0634, commercial name is Jyseleca. Small molecule preferential JAK1 inhibitor, approved in RA in European Union, Great Britain, and Japan, and in UC in European Union and Great Britain. Application for approval for ulcerative colitis was filed in Japan. Filgotinib is partnered with Gilead. Filgotinib currently is in Phase 3 trials in CD, and in a Phase 4 trial in RA

1 1tsDMARDs: targeted synthetic disease-modifying antirheumatic drugs